We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > OncoSec

News List

OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial americanpharmaceuticalreview
November 10, 2018
OncoSec announced the first patient has been treated in KEYNOTE-890, a Phase 2 clinical trial for the treatment of late-stage triple negative breast cancer (TNBC) with TAVO (intratumoral plasma encoded IL-12, or tavokinogene telseplasmid, plus electropora
OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial americanpharmaceuticalreview
November 10, 2018
OncoSec announced the first patient has been treated in KEYNOTE-890, a Phase 2 clinical trial for the treatment of late-stage triple negative breast cancer (TNBC) with TAVO (intratumoral plasma encoded IL-12, or tavokinogene telseplasmid, plus electropora
OncoSec Appoints Chief Clinical Development Officer expressbpd
October 30, 2018
The award was given in recognition of the exemplary contributions to the profession and improvement of society in line with the mission of FAPA in Asia
OncoSec Announces Positive Data from Trial of ImmunoPulse IL-12, Pembrolizumab americanpharmaceuticacreview
November 09, 2017
The updated clinical and correlative immune-focused biomarker data demonstrated a 57% progression free survival (PFS) rate at 15 months with 100% (11/11) duration of response and median PFS not yet reached.

Previous page 1 2 Next page